Articles about Krishna Ella

The first dose of the coronavirus vaccine in India will most likely be administered on January 13, a statement from a top official of the Union Health Ministry indicated on Tuesday.

The Serum Institute of India (SII) and Bharat Biotech have taken a joint pledge to ensure global access of the COVID-19 vaccines developed by them.

Bharat Biotech MS Krishna Ella on Monday said the company has "tremendous experience" in developing vaccines and their vaccine, COVAXIN, is "200% safe."

Earlier on Sunday, the Drugs Controller General of India (DCGI) announced the issuance of emergency approval to two COVID-19 vaccines for restricted use in India: Covishield and COVAXIN.

In a major move, Bharat Biotech has signed an agreement to license a nasal COVID-19 vaccine developed by the Washington University School of Medicine in St. Louis, United States.

Over the weekend, TikTok was reported to be planning legal action against Trump administration.

Ever since companies started developing vaccines for COVID-19, one big question has been on everyone's mind: how much the final, approved shot would cost to the public?

Nearly two weeks ago, AIIMS Delhi had started the Phase 1 human trial of COVAXIN — the first candidate vaccine developed indigenously in India to fight the spread of COVID-19.

The All India Institute of Medical Science (AIIMS) in Delhi has started human trials of COVAXIN, the country's first indigenously developed vaccine to prevent the novel coronavirus disease COVID-19.

In the race to develop a vaccine for the novel coronavirus disease (COVID-19), two pharma companies are leading the way from India - Bharat Biotech and Zydus Cadila.

The Indian Council of Medical Research (ICMR) on Saturday said that it is acting in accordance with globally-accepted norms by setting a mid-August target for developing a COVID-19 vaccine.